Vir Biotechnology, Inc. (VIR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.31+2.82 (+7.73%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 36.49 |
| Open | 36.56 |
| Bid | 39.11 x 800 |
| Ask | 39.21 x 1800 |
| Day's Range | 36.55 - 39.56 |
| 52 Week Range | 16.00 - 75.00 |
| Volume | 1,703,914 |
| Avg. Volume | 1,011,340 |
| Market Cap | 5.008B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.64 |
| Earnings Date | Nov 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.86 |
- Investor's Business Daily
Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid Drugs
Gilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock.
- Zacks
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
- Zacks
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
© 2021 Verizon Media. All rights reserved.
